Tetraphase Pharmaceuticals (TTPH) Receives Media Sentiment Score of 0.06
Media stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.5792501632967 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern’s analysis:
- Tetraphase Pharmaceuticals, Inc. (TTPH) – Lookout Technical Picture – Wall Street Morning (wallstreetmorning.com)
- Stock Performance Review on Generic Drugs Industry — pSivida, Tetraphase Pharma, Catalent, and Lannett – PR Newswire (press release) (prnewswire.com)
- Financial Analysis: Tetraphase Pharmaceuticals (TTPH) & SciClone Pharmaceuticals (SCLN) (americanbankingnews.com)
- Investor’s Watch List: PDL BioPharma, Inc., (NASDAQ: PDLI), Limelight Networks, Inc., (NASDAQ: LLNW), Tetraphase … – Stocks In The News (press release) (tradingnewsnow.com)
- Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : November 20, 2017 (finance.yahoo.com)
Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.69 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.57 and a one year high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company’s revenue was up 355.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.58) EPS. sell-side analysts predict that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current year.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th. BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. HC Wainwright raised their target price on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Finally, BMO Capital Markets raised their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $15.15.
WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/tetraphase-pharmaceuticals-ttph-receives-media-sentiment-score-of-0-06/1723246.html.
In other news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the transaction, the insider now owns 8,750 shares in the company, valued at approximately $52,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.